Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

The recent landscape of RSV vaccine research.

Kelleher K. et al, (2025), Ther Adv Vaccines Immunother, 13

Prevention of respiratory syncytial virus disease by immunisation.

Benzaken TR. et al, (2024), Archives of disease in childhood. Education and practice edition

Paediatric, maternal, and congenital mpox: a systematic review and meta-analysis.

Sanchez Clemente N. et al, (2024), Lancet Glob Health, 12, e572 - e588

Nirsevimab for Prevention of RSV Hospitalizations in Infants. Reply.

Faust SN. et al, (2024), N Engl J Med, 390, 1152 - 1153

Congenital CMV Monthly International Virtual Clinics: A cCMVnet European Initiative.

Gkentzi D. et al, (2024), Pediatr Infect Dis J, 43, e26 - e27

Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants.

Drysdale SB. et al, (2023), N Engl J Med, 389, 2425 - 2435

Paediatric hospital antimicrobial guidelines: a national UK review.

Shears A. et al, (2023), Arch Dis Child, 108, 946 - 947

The disease burden of respiratory syncytial virus in Infants.

Munro APS. et al, (2023), Curr Opin Infect Dis, 36, 379 - 384

Load More